Baricitinib manufacturer and brand information introduction

Baricitinib, trade name Olumiant, is a targeted immunosuppressive drug developed and produced by the American pharmaceutical company Eli Lilly (Eli Lilly). Baricitinib is a class of drugs that belongs to the class of Janus kinase (JAK) inhibitors. It mainly exerts its therapeutic effect by inhibiting the JAK signaling pathway. The JAK pathway plays a crucial role in the immune system, affecting the immune response by regulating the signaling of cytokines. Therefore, inhibiting the JAK signaling pathway can effectively control the progression of certain autoimmune diseases.

Baricitinib was originally approved to treat rheumatoid arthritis (RA), a chronic autoimmune disease in which a patient's immune system mistakenly attacks their own joints. By inhibiting JAK1 and JAK2, baricitinib reduces the inflammatory response, thereby relieving joint swelling, pain and stiffness, and significantly improving the patient's function.

In addition, the indications for baricitinib have expanded in recent years. In addition to rheumatoid arthritis, Ailemin is also approved for the treatment of alopecia areata (Alopecia Areata) and COVID-19. For patients with alopecia areata, baricitinib helps restore hair growth by regulating the abnormal response of the immune system. For patients with COVID-19, baricitinib is used to reduce the excessive immune response during severe COVID-19 infection and reduce the resulting inflammation and lung damage.

The brand information of baricitinib has gradually become known to patients. Olumiant (Olumiant), as the market name of the drug, has been approved and marketed in many countries and regions around the world. Its successful promotion is a milestone for Eli Lilly in the field of treating immune system diseases, especially in the treatment of rheumatoid arthritis and alopecia areata, baricitinib provides patients with a new treatment option.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant